Patients with resected head and neck cancers may benefit clinically from an investigational personalized vaccine.

Published Date: 10 Apr 2024

Patients with surgically removed HPV-negative head and neck squamous cell cancer (HNSCC) experienced low rates of disease relapse after receiving the personalized neoantigen vaccine TG4050, which stimulated tumor-specific immune responses.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

For incarcerated people, study shows gaps exist in quality of cancer care

2.

How a California Oncologist Making $850k Spends Money

3.

The most precise research tools for the deadliest blood cancer have been developed.

4.

Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL

5.

Big PFS Increase in Advanced Neuroendocrine Tumors With Combination Therapy


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot